Stocktoria

Neurogene Inc. NGNE

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-03-07 · LEI

Neurogene Inc. statistics & valuation

Market cap$506.1M
P / B1.9×
Return on equity-34.1%
Return on capital-38%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-130.50% -8930.30% 2016201720182019202020212022202320242025
Return on equity (%)
-25.60% -50.70% -43.50% -49.00% -17.40% -19.50% -24.20% -34.10% 2016201720182019202020212022202320242025
Shares outstanding
23.4M 23.5M 23.5M 38.0M 51.8M 55.0M 55.2M 12.8M 17.6M 21.3M 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-24.00% -45.50% -40.70% -47.20% -15.80% -37.20% -50.50% -16.30% -22.40% -31.30% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-126.50% -7720.10% 2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
-$0.64 -$1.10 -$1.04 -$4.28 -$4.24 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin—-8930.3%—————-130.5%——
Net margin—-8123.7%—————-126.3%——
FCF margin—-7720.1%—————-126.5%——
Return on assets-31.3%-22.4%-16.3%-50.5%-37.2%-15.8%-47.2%-40.7%-45.5%-24.0%
Return on equity-34.1%-24.2%-19.5%37.9%66.1%-17.4%-49.0%-43.5%-50.7%-25.6%
Current ratio16.5620.848.7212.7416.6724.6630.2816.689.9310.87

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.